O ne of the best-studied gd T cell subset in humans expresses a particular combination of TCR variable regions, Vg9 and Vd2. Vg9Vd2 T cells are mainly localized in the peripheral blood of human adults, where they represent several percent of the whole lymphoid pool (1) (2) (3) . Although this gd T cell subset is also found in the peripheral blood of most non-human primates, it has no counterpart in rodents. Vg9Vd2 T cells recognize in vitro a wide array of infected or transformed cells and are activated in vivo in various infectious and tumor contexts (4) . The widespread reactivity of Vg9Vd2 T cells is contact-dependent and involves gd TCR and nonclonal receptors (e.g., NKRs, TLRs). Following antigenic activation, Vg9Vd2 T cells display rapid and broad functional responses, such as IL-2-dependent proliferation, cytotoxicity, and proinflammatory cytokine release.
Most human Vg9Vd2 T lymphocytes are strongly and specifically activated by small nonpeptidic phosphorylated intermediates, referred to as "phosphoagonists" (PAg), of the mammalian mevalonate or the microbial deoxyxylulose-phosphate pathways (5) (6) (7) . Enhanced tumor cell recognition by Vg9Vd2 T cells correlates with upregulation of intracellular PAg levels resulting from increased cell metabolism and cholesterol biosynthesis (8) . Accordingly, pharmacologic mevalonate pathway inhibitors acting upstream or downstream of PAg biosynthesis, respectively, decrease or increase Vg9Vd2 T cell activation. Among these compounds, GMP-grade aminobisphosphonates (NBPs), which have found widespread use in bone metabolism disorders, have been identified as potent inhibitors of the synthesis of both farnesyl and geranylgeranyl lipidic residues by blocking farnesyl pyrophosphate synthase (reviewed in Ref. 9 ). Treatment of human cells with high pinocytic activity (e.g., monocytes, macrophages, dendritic cells) or dysregulated metabolism (e.g., transformed tumor cells) by NBPs, like pamidronate and zoledronate, leads to endogenous PAg accumulation and sensitizes treated cells for recognition by human Vg9Vd2 T lymphocytes (10) .
The absence of murine counterparts of Vg9Vd2 T cells and lack of tumor models in nonhuman primates have dramatically hampered assessment of the in vivo physiologic role and immunotherapeutic potential of this gd T cell subset. Decreased numbers and hyporesponsiveness of peripheral Vg9Vd2 T cells, associated with low production of proinflammatory cytokines, have been reported in patients with cancer (11, 12) . Such defects might result in impaired immune surveillance against tumors. These observations, as well as the high interindividual conservation of human peripheral Vg9Vd2 T cells, their lack of MHC restriction, and their ability to both directly lyse a broad array of tumor cells in vitro and to secrete adjuvant cytokines (e.g., IFN-g), provide a strong rationale for Vg9Vd2 T cell-based cancer immunotherapies (reviewed in Ref. 13) . In this regard, adoptive transfer of autologous human Vg9Vd2 T cells, previously activated and expanded ex vivo with PAg and recombinant human IL-2 (rhIL-2), has been performed in tumor-xenografted immunodeficient mouse models (14) and in cancer patients with solid tumors (15) (16) (17) . Repeated infusions of Vg9Vd2 T cells, either alone or with rhIL-2, were well tolerated and yielded promising signs of antitumor efficacy. Active immunotherapies relying on in vivo activation and expansion of peripheral Vg9Vd2 T cells by GMP-grade agonists (either synthetic PAg [BrHPP/IPH1101 Phosphostim]) (18) or NBPs (e.g., zoledronic acid [Zometa]) have also been evaluated in nonhuman primates and phase I/II trials in patients with hemopoietic or solid tumors (19) (20) (21) . Specific expansions and maturation to effector phenotype of peripheral Vg9Vd2 T cells have been achieved after injection of either soluble PAgs or NBPs and rhIL-2, with limited toxicity and promising antitumor efficacy. However, systemic Vg9Vd2 T cell expansions induced by these protocols were transient, and exhaustion of these proliferative responses was observed after repeated treatments (22) .
Therefore, despite encouraging results in terms of feasibility, tolerance, and antitumor efficacy, strategies targeting peripheral human Vg9Vd2 T cells need to be optimized. In this study, we show that systemic injection of NBP enhances the antitumor efficacy of adoptively transferred Vg9Vd2 T cells in xenografted immunodeficient mice. We also provide evidence that repeated treatment with both NBP and gd T cells is required to achieve efficient control of tumor growth in this in vivo model. Altogether, these results provide new insights into the design of more efficient next-generation Vg9Vd2 T cell-based immunotherapies.
Materials and Methods

Abs and flow cytometry
The following mAbs were obtained from BD Biosciences (Le Pont de Claix, France): FITC-anti-CD107a (clone H4A3) and PE-anti-TCRVg9 (clone 7B6). The following m Abs were obtained from Beckman Coulter (Villepinte, France): FITC-anti-TCRVd2 (clone IMMU389), PE-cyanin 5-anti-CD3ε (clone UCHT1) and purified anti-human TCR pan gd (clone IMMU510). Allophycocyanin-anti-IFN-g (clone B27) was obtained from BD Biosciences and used for intracellular stainings. Flow cytometry data were collected on a FACSCalibur cytometer (BD Biosciences) and analyzed with CellQuest Pro (BD Biosciences) and FlowJo (Tree Star, Ashland, OR) software.
Reagents
L-Glutamine, leukoagglutinin, streptomycin, penicillin, monensin A, PMA, ionomycin, collagenase type IV, DMEM, and RPMI 1640 medium were purchased from Sigma-Aldrich (St. Louis, MO). rhIL-2 (ProLeukin) was obtained from Chiron (Emeryville, CA). Pamidronate was obtained from Mayne Pharma (Asnières, France).
Expansion of human Vg9Vd2 T cells and PC3 tumor cells
PBMCs from healthy human donors were isolated from blood samples obtained from the Etablissement Français du Sang (Nantes, France). For specific expansion of human Vg9Vd2 T cells, fresh or frozen ex vivo PBLs (1 3 10 6 cells/ml) were incubated with pamidronate (200 mM) in complete RPMI 1640 medium (2 mM L-glutamine, 10 mg/ml streptomycin, 100 IU/ml penicillin) supplemented with 10% FCS and rhIL-2 (20 ng/ml). After 4 d, cultures were supplemented with rhIL-2 (60 ng/ml). Specific expansion of Vd2 + T cells within PBL was measured by calculating frequency and absolute number at days 10, 14, and 21 following activation. Resting Vg9Vd2 T cell lines (purity, 70-95% of Vd2 + T cells) expanded under these conditions were subsequently used in functional assays and adoptive transfer experiments. PC3 (human prostate cancer) cell line was provided by F. Paris (INSERM UMR892, Nantes, France) and kept in complete DMEM (2 mM L-glutamine, 10 mg/ml streptomycin, 100 IU/ml penicillin) with 10% FCS. Human gd T and PC3 cells were tested negative for Mycoplasma contamination.
In vitro functional assays
Tumor cells were pretreated overnight with pamidronate at the indicated concentrations, washed extensively, and cocultured together with Vg9Vd2 T cells at 37˚C in complete RPMI 1640 medium. As positive controls, nonspecific activations of Vg9Vd2 T cells were induced by a combination of PMA and ionomycin used, respectively, at 1 mM and 0.5 mg/ml. The cytolytic activity and cytokine production of activated Vg9Vd2 T cells were measured by flow cytometry. Briefly, Vg9Vd2 T cells were cocultured with tumor cells at 37˚C in the presence of 10 mM monensin and fluorochrome-labeled anti-CD107a mAb. After 4 h, gd T cells were harvested and stained with fluorochrome-labeled anti-Vg9 TCR mAb. When indicated, intracellular stainings of IFN-g were performed within the same samples.
Tumor xenografts and adoptive transfers of gd T cells in immunodeficient mice
All experiments involving animals, including their housing and care in pathogen-free conditions and experimental protocols, were conducted in accordance with the relevant laws and institutional guidelines, and were approved by the local ethics committee. Sex-matched NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were purchased from Charles River Laboratories (Wilmington, MA) and used at 6-10 wk of age. For tumor transplantation assays, the indicated numbers of human PC3 cells (1 to 10 3 10 6 cells) were resuspended in sterile PBS and injected s.c. in NSG mice. Tumor size was weekly calculated by external measurement of the diameter of s.c. tumor xenografts using a Vernier caliper. At day 14 after inoculation of tumor cells, when tumor diameter had reached a diameter .5 mm, mice were assigned randomly to four treatment groups (n = 6 mice/group): placebo (sterile PBS), pamidronate (50 mg/kg i.v. at day 14), Vg9Vd2 T cells 
Digestion of tumors into single-cell suspensions and histologic analysis
For ex vivo experiments, solid tumors were excised carefully from killed NSG mice under sterile conditions at the indicated times (1-7 d) after injection of pamidronate in vivo. Collected tumors were dissociated after a 4 h-digestion with collagenase type IV (200 U/ml). Cells were filtered through sterile 40-mm nylon filters and used for cytometric analysis and functional assays after assessment of cell yield and viability. For immunohistologic analysis, serial tissue sections (4 mm thick) were prepared from frozen tumor samples by using a cryostat (Leica CM1950, Leica Biosystems, Nanterre, France) and mounted on glass slides. After rehydration, sections were stained with mAb for human TCR pan gd. After 10 min 3,39-diaminobenzidine (DAB) incubation, tumors were counterstained with hematoxylin, according to standard histologic procedures. Images were acquired using a NanoZoomer 2.0-HT digital slide scanner and analyzed with the NDP software (Hamamatsu Photonics, Massy, France).
Statistical analysis
All data were analyzed using GraphPad Prism software (version 5; GraphPad Software). The statistical significance of differences between populations was assessed with two-tailed Student t tests. For all experiments, p , 0.05 was considered significant.
Results
Human PC3 prostate tumor s.c. xenografts in immunodeficient NSG mice
Owing to the restricted reactivity of Vg9Vd2 T cells toward human tumors and the lack of natural counterparts in rodents, our study first aimed at designing a robust model of human tumor xenografts in immunodeficient mice, which could allow assessment of the antitumor efficacy of adoptively transferred human Vg9Vd2 T cells. NSG mice represented a relevant candidate for the recipient mouse strain because they lack mature T and B cells and functional NK cells, and they are deficient in g-chain cytokine receptor signaling. In this regard, NSG mice support a better engraftment of cells of human origin (e.g., solid or circulating tumor cells, hematopoietic stem cells, PBMCs, T lymphocytes) than any other previously published immunocompromised mouse strain (23, 24) .
We defined two key criteria for selecting human cell lines as tumor xenografts and assessing the efficacy of NBP-and gd T cellbased approaches in NSG mice. First, tumor cells should not be recognized readily by Vg9Vd2 T cells, but should induce broad and sustained functional responses by allogeneic ex vivo-expanded human Vg9Vd2 T cells after NBP treatment. Next, following their engraftment in NSG mice, these cells should rapidly yield clearly discernible solid tumors. To allow tumor growth monitoring without sacrificing mice, we privileged s.c. engraftment of human tumor cells. Adherent tumor cells from the human PC3 tumor prostate cell line fulfilled both criteria. Indeed, untreated PC3 cells were modestly recognized in vitro by Vg9Vd2 T cells, but they triggered strong, specific, and dose-dependent IFN-g cytokine response and CD107a upregulation by Vg9Vd2 T cells after pamidronate treatment ( Fig. 1A and Supplemental Fig. 1) .
Moreover, analysis of the kinetics of tumor growth in vivo indicated that PC3 cells could form, in a cell number-dependent manner, easily measurable tumors in less than 6 wk following s.c. grafting in NSG mice (Fig. 1B) . When administered alone, NBP or Vg9Vd2 T cells had no detectable effects on PC3 tumor growth kinetics in NSG mice compared with untreated controls (Fig. 2B) . However, the growth of PC3 tumors was significantly decreased in mice receiving both systemic NBP injection and then human Vg9Vd2 T cells 1 day later, when compared with other conditions (Fig. 2B , right panel; 10 versus 20 mm in average diameter at week 5; p , 0.0005). 
T cell distribution within secondary lymphoid organs (lymph nodes, spleen) and tumor xenografts shows that while gd T cells preferentially located in secondary lymphoid organs immediately after infusion (peaking at week 1), they reached tumor xenografts thereafter, with a frequency peak at week 2 after gd T cell infusion (Fig. 3A) . Accordingly, immunohistochemical analysis revealed the presence of infiltrating human gd T cells only within tumors of NSG mice that received both NBP and Vg9Vd2 T cells (Fig.  3B) . Therefore, combined systemic NBP treatment and Vg9Vd2 T cells infusion yielded significant antitumor responses associated with gd T cell infiltration within tumors in vivo.
Systemic NBP treatment in NSG mice efficiently, but transiently, sensitizes PC3 xenografted tumors to Vg9Vd2 T cell responses
To gain further insight into the optimal timeframe for infusion of Vg9Vd2 T cells, we next defined the strength and kinetics of PC3 tumor cell sensitization induced by in vivo NBP treatment. To this end, tumor cells were collected from 2-wk s.c. tumor xenografts at different time points after systemic in vivo NBP treatment in NSG mice, and readily tested for their ability to induce Vg9Vd2 T cell activation in vitro. At day 1 after NBP treatment, tumor cells collected from s.c. xenografts induced strong in vitro activation of Vg9Vd2 T cells (∼60% CD107a + gd T cells; Fig. 4 ). However, NBP-induced sensitization of tumor cells to gd T cell recognition rapidly declined, reaching baseline level 3 d after treatment. Efficient recognition of tumor cells collected at late time points (e.g., from day 3 to 7) could be induced by NBP treatment in vitro, thus arguing against an escape mechanism associated with decreased susceptibility to Vg9Vd2 T cell recognition. Therefore transient gd T cell recognition of PC3 tumor cells after systemic NBP treatment is probably due to a transient increase of endogenous PAg levels (e.g., isopentenyl pyrophosphate [IPP]) within s.c. tumors.
These results indicate that, although a single systemic NBP treatment of NSG mice efficiently sensitized s.c. PC3 tumor cells to Vg9Vd2 T cell recognition, this effect was only transient (24-72 h). However, they also suggested that prolonged sensitization of tumor cells to Vg9Vd2 T cell recognition in vivo could be achievable by repeated NBP treatments.
Combination of both repeated systemic administrations of NBP and Vg9Vd2 T cells infusions strongly improves antitumor efficacy of gd T cell therapy in vivo
In line with the aforementioned kinetics of PC3 tumor cell sensitization in vivo, we next investigated whether repeated systemic NBP treatments, when combined to Vg9Vd2 T cells infusions, could improve antitumor efficacy of NBP/gd therapies in vivo (Fig. 5A) .
We first analyzed the antitumor effects of four cycles of weekly systemic NBP administrations in NSG mice carrying PC3 s.c. xenografts, combined with a single injection of Vg9Vd2 T cells performed at day 1 after the first NBP injection. As shown in Fig.  5B , this protocol did not improve tumor control by adoptively transferred gd T cells, compared with mice receiving a single NBP injection (Fig. 1) . Similarly, four cycles of weekly human Vg9Vd2 T cell infusions, combined with a single systemic administration of NBP, did not lead to any improvement of gd T cell-mediated antitumor response in vivo (Fig. 5C) . However, when both systemic NBP administrations and Vg9Vd2 T cells injections were repeated weekly for four cycles (Fig. 6A) , a strong and long-term control of PC3 tumor growth was achieved (Fig. 6B) . 
Discussion
The clinical benefit of anticancer immunotherapies using GMPgrade Vg9Vd2 T cell agonists is supported by disease stabilization and by partial and complete clinical responses observed in patients with solid or hematologic malignancies after treatment with both IL-2 and NBP (reviewed in Ref. 13 ). However, larger clinical trials performed in patients with renal cancer receiving both IL-2 and PAg did not yield significant clinical responses, although a trend for prolonged progression-free survival has been reported in the patient arm showing on average the largest Vg9Vd2 T cell expansions. Several strategies have been proposed to enhance antitumor efficacy of such active immunotherapies targeting gd T cells. Both the enhanced expression of CD16 on Vg9Vd2 PBL, compared with ab PBL, and the ability of activated Vg9Vd2 T cells to mediate Ab-dependent cellular cytotoxicity toward solid and hemopoietic tumors, either in vitro or in vivo in xenografted mice, provide a strong rationale for combination approaches involving gd agonist molecules and antitumor mAb (25) (26) (27) (28) . In this regard, treatment with anti-CD20 mAb (Rituximab), PAg, and IL-2 for patients with follicular lymphoma and tumor relapse or resistance after a first line of rituximab treatment resulted in an increased rate of complete responses, when compared with historical groups treated with a second line of rituximab alone or rituximab and IL-2 (13).
The limited efficacy of active immunotherapies that aim at triggering in vivo-specific expansion and activation of Vg9Vd2 T cells might be linked to the progressive exhaustion of the targeted T cell population after repeated treatments, and Vg9Vd2 T cell hyporesponsiveness observed in many patients before cancer treatment. Such limitations could be circumvented by adoptive T cell transfer approaches, because large numbers of Vg9Vd2 T cells can be expanded and activated in vitro using clinical-grade protocols, even in patients with cancer (29) . Thus far, disease stabilization or partial clinical response, or both, have been observed in patients with solid tumor after repeated adoptive Vg9Vd2 T cell transfer (15) (16) (17) 30) . The possibility to expand this T lymphocyte subset efficiently upon short-term culture of PBMCs from healthy donors with GMP-grade Vg9Vd2-agonist molecules and rhIL-2, as well as the lack of alloreactivity of gd T cells (31) (32) (33) (34) , could justify immunotherapies relying on the adoptive transfer of allogeneic Vg9Vd2 T cells in patients with cancer and impaired autologous Vg9Vd2 T cell expansion capacities. This is feasible based on previous studies showing limited rejection of transferred allogeneic human ab T cells carrying common HLA haplotypes, such as A1, B8, or DR3, in Caucasian patients. Importantly, this perspective must consider an efficient antitumor reactivity of allogeneic human gd T cells. In this regard, we and others have reported a strong in vitro lytic activity of Vg9Vd2 T cells against a wide set of autologous and allogeneic human tumor cells (35) . Accordingly, we obtained evidence that Vg9Vd2 T cells, expanded ex vivo from PBMCs of healthy donors, achieved robust cytolytic responses against low-passage tumor cells isolated from ovarian cancer female patients, when compared with autologous Vg9Vd2 T cell responses (Supplemental Fig. 2 ).
An attractive way to improve the efficacy of adoptive gd T cell transfer approaches might be to combine them with NBP treatments, which should sensitize tumor cells to gd T cell recognition. In this setting, the enhanced clinical benefit of combined therapies would rely on the ability of gd T cells activated ex vivo, when transfused soon after a first NBP administration, to eradicate NBPsensitized tumor cells more efficiently. Interestingly, the rationale and feasibility for such a combined approach has been supported by a recent phase I trial conducted in advanced renal carcinoma patients, which reported occurrence of a complete response and high rate of stable disease in treated patients (36) . However in this latter study, the mechanisms underlying tumor stabilization or regression have remained unclear, because the ability of NBP to enhance antitumor efficacy of adoptively transferred Vg9Vd2 T cells has not been proved formally. To address this shortcoming, we designed a preclinical in vivo model of s.c. human tumor xenografts in immunodeficient NSG mice. This robust mouse model carrying human tumor xenografts was exploited to assess the effects of combined systemic administrations of both NBP and ex vivo expanded activated human Vg9Vd2 T cells. Our results show that adoptive transfer of Vg9Vd2 T cells, performed 24 h after systemic injection of NBP, delays tumor growth in mice. Importantly, our data indicate that in vivo NBP-induced sensitization of tumor cells to human Vg9Vd2-T cell recognition lasts for a few days, which implies that repeated and combined administrations of NBP and gd T cells are both required to improve significantly the antitumor efficacy of such a combination approach. These results extend observations made recently, in a different setting by Benzaïd et al. (37) , who assessed the antitumor efficacy of a single line of NBP and IL-2 treatment in NOD/scid mice with i.p. injection of whole human PBMCs. In this study, the potency of antitumor Vg9Vd2 T cell responses in vitro and in vivo correlated with IPP/ApppI (triphosphoric acid 1-adenosin-59-yl ester 3-[3-methylbut-3-enyl] ester) levels in zoledronate-treated breast cancer cells. Interestingly, although the intracellular level of IPP is assumed to be the primary correlate of tumor cell susceptibility to Vg9Vd2 T cell recognition, high levels of intracellular IPP were detected in explanted tumor xenografts 1 d after systemic injection of zoledronate, but dropped rapidly at days 2 and 3, at time points when explanted tumor from pamidronate-treated mice still showed enhanced susceptibility to Vg9Vd2 T cell responses. This apparent discrepancy between the present and the former studies could be explained by the fact that duration of the Vg9Vd2 sensitizing effect of NBP depends on at least three distinct parameters. First, Vg9Vd2 T cells respond not only to IPP but also to ApppI, the intracellular levels of which peak at days 2-4 after zoledronate treatment, and thus could contribute to enhanced gd T cell responses at later time points. Second, responsiveness to NBP treatment greatly varies from one tumor cell line to another, and it might differ between the tumors used in these studies. Third, gd T cell responses induced by pamidronate-treated tumor cells, although weaker than those induced by zoledronate-treated cells, tend to last longer, as suggested by our in vitro studies (E. Scotet and M. Bonneville, unpublished observations).
As reported previously, IL-2, which is mainly produced by Th lymphocyte subsets and, to a much lesser extent, by activated Vg9Vd2 T cells, is an obligatory cytokine required for the expansion of activated human Vg9Vd2 T cells (38, 39) . Our study aimed at optimizing passive Vg9Vd2 immunotherapies without exogenous rhIL-2 administrations, which could lead to deleterious side effects in recipients. However, it is curious why, in treated NSG mice, the frequencies of human Vg9Vd2 T cells, following their injection without exogenous rhIL-2, peaked at week 1 within secondary lymphoid organs and at week 2 within s.c. tumor xenografts. The absolute numbers of Vg9Vd2 T cells within these sites, at different time points after injection, were not determined, which did not allow us to state the effective growth or survival of injected human gd T cells. Interestingly, a recent study has shown that, in patients with advanced colorectal cancer who received weekly injections of autologous Vg9Vd2 T cells, the frequency and absolute number of peripheral gd T cells gradually increased during the course of treatment (40) . Surprisingly, functionally active Vg9Vd2 T cells persisted for a prolonged period after the last infusions, even in the absence of exogenous rhIL-2. These results, and the observation that NBP-activated Vg9Vd2 T cells, in contrast to the resting ones, lack IL-7Ra expression and express only IL-2Rb and -g c suggest the implication of IL-2-related endogenous factors (e.g., transpresentation of IL-15) for the mechanism maintaining adoptively transferred Vg9Vd2 T cells. Because murine IL-2 is active on human T lymphocytes, although at a very low efficiency (41), we cannot exclude that host murine factors contribute to human Vg9Vd2 T cell growth and survival within xenografted NSG mice.
In conclusion, our study provides a strong preclinical rationale for repeated NBP injections combined with adoptive Vg9Vd2 T cell transfer. Importantly, our results indicate that such an approach prevents tumor expansion, but it does not eradicate preexisting tumors. This partial efficacy cannot be explained merely by impaired tumor accessibility, because infiltrating gd T cells were detected even within the tumor bed. Nevertheless, the hypoxic environment within the tumor might enhance resistance to gd T cell-mediated immune attack. In this regard, one method of circumventing this escape mechanism and further improve efficacy of the present combination approach might be to use low-dose chemotherapies, which are known to enhance gd T cell susceptibility of zoledronate-sensitized tumor cells (42) ; cytokines known to boost antitumor cytotoxic and proinflammatory responses of gd T cells, such as IL-21 (43) and IL-27 (44); or TLR ligands (45) .
